Страница 1 от 24 резултата
FIELD OF THE INVENTION
The current invention relates to the field of medicine and in particular to the use of LPS detoxifying and neutralizing enzymes. The present invention also relates to the field of pharmacy and in particular to the pharmaceutical use of alkaline phosphatase enzymes.
BACKGROUND
FIELD OF THE INVENTION
This invention relates to a method of inhibiting Protein Tyrosine Phosphatase 1B (PTP1B) and/or T-cell Protein Tyrosine Phosphatase (TC-PTP) and/or Protein Tyrosine Phosphatases (PTPases) having an aspartic acid (Asp) in position 48 (PTP1B numbering, Chernoff et al., Proc.
FIELD OF THE INVENTION
This invention relates to the field of protein tyrosine phosphatase inhibition.
BACKGROUND OF THE INVENTION
This invention relates to a novel class of phosphonic acid derivatives that are inhibitors of PTP-1B.
Reversible protein tyrosine phosphorylation, coordinated by the
FIELD OF THE INVENTION
This invention relates to the field of protein tyrosine phosphatase inhibition.
BACKGROUND OF THE INVENTION
This invention relates to a novel class of phosphonic acid derivatives that are inhibitors of PTP-1B.
Reversible protein tyrosine phosphorylation, coordinated by the
BACKGROUND OF THE INVENTION
The invention relates to phosphatases and more in specific to (genetically) modified phosphatases, pharmaceutical compositions comprising (genetically) modified phosphatases and the use of (genetically) modified phosphatases for treating or curing for example sepsis,
TECHNICAL FIELD OF THE INVENTION
The invention relates to the regulation of human protein phosphatase IIC-like enzyme activity for therapeutic effects.
BACKGROUND OF THE INVENTION
The protein phosphorylation/dephosphorylation cycle is one of the major regulatory mechanisms employed by eukaryotic
FIELD OF THE INVENTION
This invention is directed to methods of using thiazolidine derivatives to treat cancer or inflammation in a mammal.
BACKGROUND OF THE INVENTION
Protein tyrosine phosphorylation is an important mechanism for transmitting extracellular stimuli in biochemical and cellular events
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to novel phosphotetrahydropyran compounds, primarily derivatives of mannose-6-phosphate, and their use in treating diseases or disorders that are mediated at least in part by T lymphocyte emigration from
BACKGROUND OF THE INVENTION
This invention relates to a biocompatible, non-inflammatory, collagen conjugate material, described herein in the form of a porous membrane structure, and to a process for making this material. While individual components of this system are known in the art and in the
This application is the National Stage of Application No. PCT/EP2006/046543, filed on Dec. 6, 2006, which claims benefit under 35 U.S.C. .sctn.119(a-d) of U.S. Provisional Application No. 60/748,491, filed Dec. 8, 2005, the contents of which are incorporated herein by reference in their
FIELD OF THE INVENTION
The present invention provides methods for modulating SET activity by contacting SET with a binding agent. In one embodiment, the binding agent is an ApoE peptide derivative. The invention provides methods for the treatment of inflammatory and neurological conditions by
BACKGROUND OF THE INVENTION
1. Technical Field
The present invention relates generally to compositions and methods useful for treating conditions associated with defects in cell proliferation, cell differentiation, and cell survival. The invention is more particularly related to double-stranded RNA
BACKGROUND
Fibroblast-like synoviocytes (FLS) in the intimal lining of the joint synovium control the composition of the synovial fluid and extracellular matrix (ECM) of the joint lining. In rheumatoid arthritis (RA), FLS become aggressive and invasive, contributing to many aspects of RA pathology.
BACKGROUND OF THE INVENTION
The field of the invention is treating post-seizure patients to interfere with epileptogenesis.
The highest incidence of seizures during lifetime is found in the neonatal period and neonatal seizures lead to a propensity for epilepsy and long-term cognitive deficits. Here
FIELD OF THE INVENTION
The invention relates to the use of tricyclic chemical modulators of PPA2 and FOXO transcription factor proteins to treat cancer, proteotoxicity induced neurodegeneration, stress-induced depression, inflammation, acne, and viral infections.
BACKGROUND
Protein kinases have